+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effects of teplizumab compared with a placebo in individuals aged 1 to 25 years who have recently been diagnosed with Stage 3 type 1 diabetes. This Phase 3, multicenter, randomized, double-blind study aims to measure changes in blood sugar control and the ability to reduce prandial insulin use over 52 weeks. Both groups will continue their standard insulin therapy during the study. Participants will receive either teplizumab or a matching placebo through intravenous infusions, with teplizumab doses gradually increasing. The study includes two groups one receiving the study drug and the other receiving placebo infusions. The total study period for each participant lasts about 84 weeks 19 months, during which participants are closely monitored. Throughout the study, participants will be regularly evaluated for blood sugar levels, insulin use, and markers of diabetes control including glycated hemoglobin HbA1c, C-peptide levels, and glucose monitoring. Safety will be assessed by tracking adverse events and immune responses. The research team will monitor participants at specified intervals up to 78 weeks to assess treatment effects and safety.

Age: 1Year - 25YearsAll GendersPhase 3
202 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
P

Actively Recruiting

Researchers are conducting a phase 3 clinical trial comparing two treatment combinations for adults with ER-positive, HER2-negative advanced breast cancer who have not received prior systemic anti-cancer treatment for this condition. The study aims to evaluate the effectiveness and safety of palazestrant combined with ribociclib versus letrozole combined with ribociclib. Participants include men and women with locally advanced or metastatic breast cancer not suitable for curative therapy. Participants are randomly assigned to one of two groups. One group receives palazestrant 90 mg once daily, ribociclib 600 mg once daily on days 1-21 of a 28-day cycle, and a placebo matching letrozole daily. The other group receives letrozole 2.5 mg once daily, ribociclib 600 mg once daily on days 1-21 of a 28-day cycle, and a placebo matching palazestrant daily. Treatment cycles repeat every 28 days, and the study includes approximately 1,000 participants worldwide. During the study, participants will be monitored for disease progression and overall survival, with primary measurements taken from the date of randomization until disease progression or death, estimated up to 3.5 years. Safety, drug levels, and patient-reported health outcomes will be assessed regularly. The trial includes long-term follow-up for up to 5.5 years to evaluate overall survival. Participants will have scheduled visits for assessments and monitoring throughout their involvement in the trial.

Age: 18Years +All GendersPhase 3
200 locations
L

Actively Recruiting

This research focuses on Stage 2 Type 1 Diabetes T1D, an early phase marked by abnormal blood sugar levels without clear symptoms. The study aims to gather information about patients with Stage 2 T1D and to observe the long-term effects of TZIELD teplizumab-mzwv, a drug approved by the U.S. FDA to delay the progression to clinical T1D in adults and children aged 8 years and older. This is an observational study where no treatments are administered by the researchers. Instead, patients who are either about to start or have recently started TZIELD treatment within six months, as well as patients not receiving TZIELD, will be followed. The study records the use of TZIELD as prescribed in real-world clinical practice without interference. Participants will be monitored for up to about 10 years to track adverse events, serious adverse events, maternal and infant outcomes if exposed during pregnancy, and infant development up to 12 months after birth. Data will be collected through routine clinical assessments and safety monitoring, helping to understand the long-term safety of TZIELD in this patient group.

All AgesAll Genders
37 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of lifileucel combined with pembrolizumab compared to pembrolizumab alone in adults with untreated, unresectable or metastatic melanoma, specifically Stage IIIC, IIID, or IV. This Phase 3, multicenter, randomized, open-label study allows some participants from the pembrolizumab group to switch to lifileucel if their disease progresses. Participants in the lifileucel plus pembrolizumab group first have a tumor sample removed to create the lifileucel treatment. They receive pembrolizumab followed by a lymphodepletion regimen, lifileucel infusion, and IL-2, then continue pembrolizumab every 6 weeks until disease progression. Those in the pembrolizumab alone group receive pembrolizumab every 6 weeks, with an optional crossover to lifileucel if confirmed disease progression occurs. During the study, participants undergo assessments including tumor measurements by RECIST 1.1, organ function tests, and monitoring for adverse events. The main outcomes measured are objective response rate and progression-free survival over 5 years, with additional evaluations of overall survival, duration of response, and safety over up to 7 years. Participants may be followed and evaluated regularly throughout this period.

Age: 18Years - 70YearsAll GendersPhase 3
82 locations